Suven Life Sciences had announced the grant of five patents in various countries. These patents include the class of selective 5 HT (Hydroxytryptamine) compounds relating to the treatment of cognitive impairment leading to neurodegenerative diseases
Suven Life Sciences had announced the grant of five patents in various countries. These patents include the class of selective 5 HT (Hydroxytryptamine) compounds relating to the treatment of cognitive impairment leading to neurodegenerative diseases